Atlas Trials

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Clinical trial NCT06291376 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06291376
Sponsor
Alexion Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Immunoglobulin A NephropathyIgAN
Start date
2024-03-29
Primary completion
2026-01-05
Enrollment
579

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.